

About CDC's Work to Combat Antibiotic Resistance

With these investments, the Centers for Disease Control & Prevention (CDC), in partnership with health departments, academia, and healthcare, is transforming how the nation combats and slows antibiotic resistance at all levels, ensuring our ability to stand up a full, faster response to protect Americans from this threat.

These investments will better protect patients through:

Detection and Response

- Rapid detection and faster response to outbreaks and emerging resistance related to healthcare-associated infections, foodborne bacteria, and gonorrhea—to contain and control spread
- Gold-standard lab capacity offered to all state and regional labs through CDC's Antibiotic Resistance Laboratory Network

Prevention of Infections

- Improve prevention of healthcare-associated infections, foodborne illness, and gonorrhea
- Empowered networks for prevention across healthcare and communities for threats like *Clostridium difficile*, methicillin-resistant *Staphylococcus aureus* (MRSA), and "nightmare bacteria" carbapenem-resistant Enterobacteriaceae (CRE)
- Insights for research innovation and better patient care

Improving Antibiotic Use

- Ensure antibiotics work to protect patients from life-threatening infections or sepsis
- Protect patients from unintended consequences associated with antibiotic use, including adverse drug events

These investments work toward meeting national goals to prevent drug-resistant infections as outlined in the National Action Plan for Combating Antibiotic-Resistant Bacteria.

See CDC's AR investments by state at
wwwn.cdc.gov/ARInvestments.